Orphagen Discovers And Develops Small Molecules To Drug Targets That Have Significant Unrealized Potential In Areas Of High Clinical Needwe Focus On The Unexplored Ororphanmembers Of The Nuclear Receptor Familynuclear Receptors Have Been A Rich Source Of Successful Drugs Orphagen Has Identified Drug Like Small Molecules To Several Orphan Nuclear Receptors And Has Described Efficacy In Animal Models Of Diseasean Early Success Led To A Partnership With Japan Tobaccojtpharma To Discover And Develop Oral Drugs To Treat Psoriasis And Other Autoimmune Diseasesthis Partnership Was The First In The Industry For The Nuclear Receptor Ror Gammajte 451A Product Of The Jt Pharma Partnershipentered Phase 2 Trials This Yearin 2019Orphagen Has Two Major Internal Programsone Is To Develop Antagonists To The Orphan Nuclear Receptor Steroidogenic Factor 1Sf 1For Adrenocortical Canceraccand Other Endocrine Conditionsthe Second Focuses On Inflammatory Disease
No conferences found for this company.
| Company Name | Orphagen Pharmaceuticals Inc |
| Country |
United States
|
| Address | 11558 Sorrento Valley Rd Suite 4san Diego Ca 92121 |
| Telephone | Login to View |
| Login to View |
